What one share of Aardvark Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.
Aardvark Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$3.21 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.19 |
| Cash and investments | $3.37 |
| Book value | $3.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$5.15 | $0.03 | −$4.55 | — | −$13.44 |
| 2025 | $0.00 | −$2.93 | $0.00 | −$2.77 | — | $4.89 |
Common questions about Aardvark Therapeutics
How much does one share of Aardvark Therapeutics earn?
Over the last 12 months, Aardvark Therapeutics lost $3.21 for each share.
Does Aardvark Therapeutics pay a dividend?
Aardvark Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aardvark Therapeutics’s book value per share?
Aardvark Therapeutics’s book value is $3.42 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aardvark Therapeutics have?
Each share of Aardvark Therapeutics has $3.37 of cash and investments, as of June 30, 2026.
What is Aardvark Therapeutics’s free cash flow per share?
−$3.19 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.